Cargando…

Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2

Neutralizing agents against SARS-CoV-2 are urgently needed for the treatment and prophylaxis of COVID-19. Here, we present a strategy to rapidly identify and assemble synthetic human variable heavy (VH) domains toward neutralizing epitopes. We constructed a VH-phage library and targeted the angioten...

Descripción completa

Detalles Bibliográficos
Autores principales: Bracken, Colton J., Lim, Shion A., Solomon, Paige, Rettko, Nicholas J., Nguyen, Duy P., Zha, Beth Shoshana, Schaefer, Kaitlin, Byrnes, James R., Zhou, Jie, Lui, Irene, Liu, Jia, Pance, Katarina, Zhou, Xin X., Leung, Kevin K., Wells, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356808/
https://www.ncbi.nlm.nih.gov/pubmed/33082574
http://dx.doi.org/10.1038/s41589-020-00679-1
_version_ 1783737011605078016
author Bracken, Colton J.
Lim, Shion A.
Solomon, Paige
Rettko, Nicholas J.
Nguyen, Duy P.
Zha, Beth Shoshana
Schaefer, Kaitlin
Byrnes, James R.
Zhou, Jie
Lui, Irene
Liu, Jia
Pance, Katarina
Zhou, Xin X.
Leung, Kevin K.
Wells, James A.
author_facet Bracken, Colton J.
Lim, Shion A.
Solomon, Paige
Rettko, Nicholas J.
Nguyen, Duy P.
Zha, Beth Shoshana
Schaefer, Kaitlin
Byrnes, James R.
Zhou, Jie
Lui, Irene
Liu, Jia
Pance, Katarina
Zhou, Xin X.
Leung, Kevin K.
Wells, James A.
author_sort Bracken, Colton J.
collection PubMed
description Neutralizing agents against SARS-CoV-2 are urgently needed for the treatment and prophylaxis of COVID-19. Here, we present a strategy to rapidly identify and assemble synthetic human variable heavy (VH) domains toward neutralizing epitopes. We constructed a VH-phage library and targeted the angiotensin-converting enzyme 2 (ACE2) binding interface of the SARS-CoV-2 Spike receptor-binding domain (Spike-RBD). Using a masked selection approach, we identified VH binders to two non-overlapping epitopes and further assembled these into multivalent and bi-paratopic formats. These VH constructs showed increased affinity to Spike (up to 600-fold) and neutralization potency (up to 1400-fold) on pseudotyped SARS-CoV-2 virus when compared to standalone VH domains. The most potent binder, a trivalent VH, neutralized authentic SARS-CoV-2 with half-maximal inhibitory concentration (IC(50)) of 4.0 nM (180 ng/mL). A cryo-EM structure of the trivalent VH bound to Spike shows each VH domain engaging an RBD at the ACE2 binding site, confirming our original design strategy.
format Online
Article
Text
id pubmed-8356808
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-83568082021-08-11 Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2 Bracken, Colton J. Lim, Shion A. Solomon, Paige Rettko, Nicholas J. Nguyen, Duy P. Zha, Beth Shoshana Schaefer, Kaitlin Byrnes, James R. Zhou, Jie Lui, Irene Liu, Jia Pance, Katarina Zhou, Xin X. Leung, Kevin K. Wells, James A. Nat Chem Biol Article Neutralizing agents against SARS-CoV-2 are urgently needed for the treatment and prophylaxis of COVID-19. Here, we present a strategy to rapidly identify and assemble synthetic human variable heavy (VH) domains toward neutralizing epitopes. We constructed a VH-phage library and targeted the angiotensin-converting enzyme 2 (ACE2) binding interface of the SARS-CoV-2 Spike receptor-binding domain (Spike-RBD). Using a masked selection approach, we identified VH binders to two non-overlapping epitopes and further assembled these into multivalent and bi-paratopic formats. These VH constructs showed increased affinity to Spike (up to 600-fold) and neutralization potency (up to 1400-fold) on pseudotyped SARS-CoV-2 virus when compared to standalone VH domains. The most potent binder, a trivalent VH, neutralized authentic SARS-CoV-2 with half-maximal inhibitory concentration (IC(50)) of 4.0 nM (180 ng/mL). A cryo-EM structure of the trivalent VH bound to Spike shows each VH domain engaging an RBD at the ACE2 binding site, confirming our original design strategy. 2020-10-20 2021-01 /pmc/articles/PMC8356808/ /pubmed/33082574 http://dx.doi.org/10.1038/s41589-020-00679-1 Text en http://www.nature.com/authors/editorial_policies/license.html#termsUsers may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Bracken, Colton J.
Lim, Shion A.
Solomon, Paige
Rettko, Nicholas J.
Nguyen, Duy P.
Zha, Beth Shoshana
Schaefer, Kaitlin
Byrnes, James R.
Zhou, Jie
Lui, Irene
Liu, Jia
Pance, Katarina
Zhou, Xin X.
Leung, Kevin K.
Wells, James A.
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
title Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
title_full Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
title_fullStr Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
title_full_unstemmed Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
title_short Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
title_sort bi-paratopic and multivalent vh domains block ace2 binding and neutralize sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356808/
https://www.ncbi.nlm.nih.gov/pubmed/33082574
http://dx.doi.org/10.1038/s41589-020-00679-1
work_keys_str_mv AT brackencoltonj biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT limshiona biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT solomonpaige biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT rettkonicholasj biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT nguyenduyp biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT zhabethshoshana biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT schaeferkaitlin biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT byrnesjamesr biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT zhoujie biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT luiirene biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT liujia biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT pancekatarina biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT zhouxinx biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT leungkevink biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2
AT wellsjamesa biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2